Abstracts Archive - Page 2526 of 2607 - ACR Meeting Abstracts

Abstract Number: 1164 • 2012 ACR/ARHP Annual Meeting
Orofacial Anomalies in Children with Confirmed Juvenile Idiopathic Arthritis
Bernd Koos¹, Franka Stahl de Castrillon², Robert Ciesielski¹ and Nikolay Tzaribachev³, ¹Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, ²Department of Orthodontics, University of Rostock, Germany, Department of Orthodontics, University of Rostock, Germany, Rostock, Germany, ³Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany
Background/Purpose: In children with juvenile idiopathic arthritis (JIA) temporomandibular joints (TMJ) are affected in up to 96% of the patients, where TMJ arthritis is frequently…
Abstract Number: 1165 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Nicoletta Solari¹, Elena Palmisani¹, Alessandro Consolaro¹, Sara Dalprà¹, Benedetta Schiappapietra¹, Giulia Bracciolini¹, Silvia Rosina¹, Giorgia Negro¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The advent of new therapies for juvenile idiopathic arthritis (JIA), particularly the introduction of biologic medications, has increased considerably the potential for treatment benefit,…
Abstract Number: 1166 • 2012 ACR/ARHP Annual Meeting
Clinical and Therapeutic Features of 312 Patients with Macrophage Activation Syndrome Enrolled in a Multinational Survey
Sergio Davì¹, Francesca Minoia¹, Erkan Demirkaya², Chiara Suffia³, Mario Abinun⁴, Amita Aggarwal⁵, Nuray Aktay Ayaz⁶, Maria Alessio⁷, Jordi Anton⁸, Maria Apaz⁶, Tadej Avcin⁹, Patrizia Barone¹⁰, Blanca E. Bica¹¹, Isabel Bolt¹², Luciana Breda¹³, Vyacheslav Chasnyk¹⁴, Rolando Cimaz⁶, Fabrizia Corona⁶, Ruben Cuttica¹⁵, Gianfranco D'Angelo¹⁶, AnnaCarin Horne¹⁷, Nicola Ruperto¹⁸, Alberto Martini¹⁹, Randy Q. Cron²⁰ and Angelo Ravelli⁶, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²International Investigator Consortium for MAS Diagnostic Criteria, Ankara, Turkey, ³Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy, ⁴International Investigator Consortium for MAS Diagnostic Criteria, Newcastle upon Tyne, United Kingdom, ⁵Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ⁶Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ⁷Department of Pediatrics, Rheumatology Unit, University of Naples Federico II, Naples, Italy, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹International Investigator Consortium for MAS Diagnostic Criteria, Ljubljana, Slovenia, ¹⁰Azienda Policlinico Università di Catania, Catania, Italy, ¹¹International Investigator Consortium for MAS Diagnostic Criteria, Rio de Janeiro, Brazil, ¹²Kinderspital Zuerich, Universitaetskinderklinik, Zurich, Switzerland, ¹³International Investigator Consortium for MAS Diagnostic Criteria, Chieti, Italy, ¹⁴Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁵International Investigator Consortium for MAS Diagnostic Criteria, Buenos Aires, Argentina, ¹⁶International Investigator Consortium for MAS Diagnostic Criteria, Ancona, Italy, ¹⁷Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, ¹⁸Istituto Gaslini, Genova, Italy, ¹⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ²⁰Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: A multinational collaborative effort aimed to develop a new set of criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) has…
Abstract Number: 1167 • 2012 ACR/ARHP Annual Meeting
Golimumab in 25 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA
Irene Pontikaki¹, Orazio De Lucia², Maurizio Gattinara³, Alessandra Salmaso¹, Pier Luigi Meroni⁴ and Valeria Gerloni¹, ¹Pediatric Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ²Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ³Pediatric Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁴Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: Biological agents licensed in JIA have demonstrated a favourable benefit-to-risk profile. Nevertheless, intolerance, loss and lack of efficacy or adverse events have led to…
Abstract Number: 1168 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis of Early Biologic Treatment in Polyarticular Juvenile Idiopathic Arthritis
Nadia Luca¹, Heather Burnett², Wendy Ungar², Timothy Beukelman³, Brian M. Feldman⁴, Gwen Schwartz⁵ and Ahmed Bayoumi⁶, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Health Economics Unit, St. Michael's Hospital, Toronto, ON, Canada, ⁶General Internal Medicine, Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: The optimal timing of high cost biologic therapies in the treatment of polyarticular juvenile idiopathic arthritis (JIA) is uncertain. We evaluated the economic and…
Abstract Number: 1169 • 2012 ACR/ARHP Annual Meeting
Obstetrical Complications in Women with Juvenile Idiopathic Arthritis
Evelyne Vinet¹, Sasha Bernatsky², Mohammed Kaouache², Christian A. Pineau³, Ann E. Clarke⁴, Elizabeth Hazel⁵, Ciaran M. Duffy⁶, Anick Bérard⁷ and Debbie Ehrmann Feldman⁸, ¹McGill University Health Center, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷Université de Montréal, Montréal, QC, Canada, ⁸Rehabilitation, Université de Montréal, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) most often affects women before childbearing age. Patients with JIA and their parents often ask about the potential impact of…
Abstract Number: 1170 • 2012 ACR/ARHP Annual Meeting
Folate Usage in Methotrexate -Treated Juvenile Idiopathic Arthritis Patients Is Inconsistent and Highly Variable
Gil Amarilyo¹, Ornella J. Rullo², Deborah K. McCurdy³, Jennifer M.P. Woo¹ and Daniel Furst⁴, ¹Pediatrics/Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ²Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, ⁴David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA
Background/Purpose: Low-dose weekly methotrexate (MTX) is the first-choice second-line drug in the treatment of juvenile idiopathic arthritis (JIA). Folate (as either Folic acid (FA) or…
Abstract Number: 1171 • 2012 ACR/ARHP Annual Meeting
Validation of BASDAI and BASFI in Children with Spondyloarthritis
Alisa C. Rachlis¹, Bertha Wong², Kristi J. Whitney-Mahoney³, Michelle Batthish², Michelle Anderson⁴, JoAnne Marcuz⁴, Margaret Reaume⁴, Ashley DeLaurier⁵, Ronald Laxer⁴, Brian M. Feldman⁵ and Shirley M. Tse², ¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Pediatric Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Rehab Services, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile-onset Spondyloarthritis (JSpAs), referred to as Enthesitis-Related Arthritis (ERA) subtype under the International League of Associations for Rheumatology (ILAR) classification is characterized by arthritis…
Abstract Number: 1172 • 2012 ACR/ARHP Annual Meeting
Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era
Charalampia Papadopoulou¹, Maria I. Gonzalez¹, Juan C. Nieto¹, Mikhail Kostik², Marek Bohm¹, Stefano Lanni¹, Valentina Muratore³, Alessandro Consolaro¹, Alberto Martini⁴ and Angelo Ravelli⁵, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Hospital Pediatrics, State Pediatric Medical University, Saint-Petersburg, Russia, ³Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁵University of Genova, Genova, Italy
Background/Purpose: Intra-articular corticosteroid injection (IACI) therapy in juvenile idiopathic arthritis (JIA) is generally considered for the treatment of children with arthritis in a small number…
Abstract Number: 1173 • 2012 ACR/ARHP Annual Meeting
Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 175 Newly-Diagnosed Patients
Alessandro Consolaro¹, Giorgia Negro¹, Nicoletta Solari¹, Cristina Ferrari¹, Sergio Davì¹, Silvia Pederzoli¹, Giulia Bracciolini¹, Maria C. Gallo¹, Alberto Martini² and Angelo Ravelli³, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ³Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The recent advances in the management of juvenile idiopathic arthritis (JIA) have increased considerably the potential to achieve disease remission or, at least, low…
Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Ricardo A. G. Russo¹ and Marìa M. Katsicas², ¹Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…
Abstract Number: 1175 • 2012 ACR/ARHP Annual Meeting
Decreased Frequency of Th17 Cells in Early Rheumatoid Arthritis
Irene Arroyo-Villa¹, M. Belén Bautista-Caro¹, Alejandro Balsa², Pilar Aguado², Laura Nuño², Gema Bonilla³, Amaya Puig-Kröger⁴, Emilio Martín-Mola² and M. Eugenia Miranda-Carús², ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Hospital La Paz-IdiPaz, Madrid, Spain, ³Rheumatology, Hospital La Paz, Madrid, Spain, ⁴Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: Our objective was to examine the frequency and phenotype of Th17 cells in the peripheral blood of early RA (eRA) patients. Methods: CD4+ T…
Abstract Number: 1136 • 2012 ACR/ARHP Annual Meeting
Aesthetic Dissatisfaction in Hand Osteoarthritis Patients, Its Impact and Risk Factors
R. Liu, L.J.J. Beaart-van de Voorde, T.W.J. Huizinga and M. Kloppenburg, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Hand osteoarthritis (HOA) leads to aesthetic damage and is rarely studied. We aim to investigate in HOA patients the prevalence of dissatisfaction with the…
Abstract Number: 1137 • 2012 ACR/ARHP Annual Meeting
Clinimetric Properties of a New Outcome Measure:the Hand-Osteoarthritis Aesthetic Damage Index
N. Bellamy and Joan Hendrikz, Conrod, The University of Queensland, Herston, Queensland, Australia
Background/Purpose: The 2006 OARSI Guidelines for hand OA clinical trials, recognised the potential value of an aesthetic damage assessment, but acknowledged the absence of any…
Abstract Number: 1138 • 2012 ACR/ARHP Annual Meeting
Nonpharmacologic and Pharmacologic Therapy Utilization by Primary Care Providers for Hand Osteoarthritis-Comparative Review by Electronic Health Record Data Mining and in-Home Visit Verification
Gale A. McCarty, President, Rheum.Ed Consulting, Harborside, ME
Background/Purpose: To compare current utilization of usual nonpharmacologic (NP) and pharmacologic (P) therapies for hand osteoarthritis (OA) by primary care providers (PCPs) and patients (Pts)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].